🇺🇸 FDA
Patent

US 9018216

Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof

granted A61KA61K31/506A61P

Quick answer

US patent 9018216 (Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof) held by Vertex Pharmaceuticals Incorporated expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/506, A61P, A61P31/04